University-Spinout Venture-Builder Architect

The mandate

Translational grants, disclosures and entrepreneur programmes have grown, yet promising discoveries enter company formation through inconsistent routes. Some teams incorporate before customer and freedom-to-operate questions are understood; others remain in grant cycles after commercial evidence is sufficient. The defined problem is to design a venture-building service that allocates scarce founder, laboratory and proof capital to explicit uncertainties while preserving investigators’ research obligations and voluntary participation.

The named deliverable is a University-Spinout Venture-Builder Architecture covering opportunity framing, disclosure triage, technical and use-case evidence, founder intent, team gaps, intellectual-property dependency, translational work, market learning, regulatory route, company timing, equity discussion, conflicts, investment readiness and post-formation handoff. It will include venture archetypes, decision rights, evidence gates, studio playbooks, resource models, stop and recycle routes, portfolio measures and a costed two-cohort launch plan.

Five milestones govern six months. Week four reconstructs twenty discovery journeys across life science, climate, advanced materials and software. Week nine defines archetypes and the uncertainty-to-resource model. Week fourteen completes six founder studios using live opportunities. Week nineteen tests investment-readiness decisions with three independent panels. Week twenty-four delivers the accepted architecture, individual dispositions, governance changes, skills plan, systems requirements and twelve-month commissioning backlog.

Acceptance rests with the pro-vice-chancellor and Investment Committee; researchers, research-integrity officers, intellectual-property counsel and authorised investors retain their decisions. Work is accepted only when internal teams can route eight unseen opportunities through the gates, founder consent is explicit, evidence expenditure follows the material uncertainty, a stop does not prejudice continuing research, and panel judgments reconcile to documented proof rather than presentation polish or academic seniority.

The client provides de-identified disclosures, grant histories, laboratory access permissions, licensing files, founder interviews, past investment papers, cost data, policies and controlled investor participation. Consultants will not value intellectual property, negotiate equity, select founders, direct research, provide legal or investment advice, handle confidential results outside approved systems or solicit capital. Live incorporation, licensing transactions, fund management and technology build are excluded; missing specialist opinions remain named dependencies.

Why this is external work

Commercialisation teams know the portfolio, but current programmes were built around funding instruments and organisational boundaries rather than the sequence of venture uncertainty. The university wants neutral operating design before expanding its studio. External venture-building experience can expose premature incorporation and endless validation alike without turning consultants into investment selectors or research managers.

What you will own

• Reconstruct twenty discovery journeys from disclosure and translational grant through company formation, licensing, recycle or evidence-based stop.
• Segment venture archetypes by technical uncertainty, adoption route, regulatory burden, founder intent, capital intensity and university dependency.
• Define decision rights among investigators, commercialisation teams, research integrity, intellectual-property counsel, founders, committees and outside capital.
• Build evidence gates that match experiments, customer learning, team formation and spending to the next irreversible decision.
• Facilitate six live founder studios and three panels while recording disagreement, conflicts, missing proof and changed dispositions.
• Specify portfolio measures for learning velocity, founder readiness, evidence quality, resource concentration, recycling and post-formation dependency.
• Deliver the accepted architecture, cohort designs, opportunity dispositions, governance changes and costed twelve-month commissioning plan.

Candidate qualifications

• Has built university spinouts or deep-technology ventures across more than one scientific and commercialisation archetype.
• Can evidence a venture delayed, redirected or stopped because the decisive uncertainty differed from the assumed funding milestone.
• Understands translational research, founder formation, intellectual-property dependency, customer discovery, regulation, company design and venture finance.
• Has facilitated academics, technology-transfer professionals and investors without appropriating research, legal or investment decisions.
• Can distinguish scientific novelty, product evidence, company readiness, founder readiness and external investability in portfolio reviews.
• Has left internal teams with repeatable venture studios and evidence gates that operate without continuing consultant interpretation.

Non-negotiables

• Can complete ten Cambridge and Oxford laboratory immersions, six founder studios and three evidence panels in six months.
• Will not value intellectual property, negotiate equity, choose founders, direct research or solicit capital.
• Brings direct deep-technology venture-building experience; general innovation facilitation or accelerator mentoring is insufficient.
• Will preserve founder refusal, stopped opportunities, inconclusive evidence and continuing academic routes in portfolio reporting.

1. 49 words maximum. Which spinout milestone most often arrived before the venture uncertainty it was meant to resolve?
2. 49 words maximum. Describe one discovery you redirected without weakening the underlying research programme.
3. 49 words maximum. What evidence separates an investable company from a scientifically important licensing opportunity?